Key result
An edrophonium-hyoscine butylbromide mixture prevented initial bradycardia compared to an edrophonium-atropine mixture during reversal of neuromuscular blockade in infants and children.
Why the study?
Does a mixture of edrophonium and hyoscine butylbromide prevent edrophonium-induced bradycardia better than an edrophonium-atropine mixture in infants and children?
Does a mixture of edrophonium and hyoscine butylbromide prevent edrophonium-induced bradycardia better than an edrophonium-atropine mixture in infants and children?
Hyoscine butylbromide is an effective substitute for atropine to prevent edrophonium-induced bradycardia during neuromuscular blockade reversal in infants and children.
May support hyoscine butylbromide as atropine alternative in pediatric reversal; leaves open need for randomized confirmation.
The effectiveness of hyoscine butylbromide in the prevention of edrophonium-induced bradycardia was assessed in 50 infants and children. A mixture of edrophonium (1.0 mg/kg) and either atropine (0.01 mg/kg) or hyoscine butylbromide (0.4 mg/kg) was administered to reverse the effects of tubocurarine. An initial bradycardia followed the injection of the edrophonium-atropine mixture. In contrast there was no initial decrease in heart rate after the administration of the edrophonium-hyoscine butylbromide mixture. Hyoscine butylbromide can be used with advantage as a substitute for atropine in edrophonium reversal in infants and children.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (1988) studied Neuromuscular blockade (n=50). Edrophonium-hyoscine butylbromide mixture vs. Edrophonium-atropine mixture (edrophonium 1.0 mg/kg and atropine 0.01 mg/kg) was evaluated on Heart rate changes (prevention of edrophonium-induced bradycardia). An edrophonium-hyoscine butylbromide mixture prevented initial bradycardia compared to an edrophonium-atropine mixture during reversal of neuromuscular blockade in infants and children.